Medical Microinstruments (MMI) has closed a $125 million Series D financing round, positioning the company to broaden the reach of its Symani robotic system across the United States and key international markets. The funds will also support ongoing clinical research, including efforts aimed at potential applications in Alzheimer’s disease.
Advancing Precision in Soft Tissue Surgery
The Symani platform is built for open soft tissue microsurgery. It enables surgeons to repair delicate structures such as lymphatic vessels and nerves with a high degree of control. The system filters out natural hand tremors and converts the surgeon’s hand and wrist movements into precise motions of its miniaturized instruments. Both the robot and its companion Synaptix digital platform are designed for easy movement between operating rooms.
MMI already holds FDA de novo classification for microsurgery, granted in 2024, along with clearance for soft tissue dissection the following year. The technology also carries CE mark approval in Europe. To date, the company reports that roughly 3,500 complex microsurgical procedures—primarily cancer- and trauma-related reconstructions—have been completed worldwide using Symani. The installed base currently stands at about 50 systems.
Leadership Perspective and Investor Support
“We’ve proven there is demand for robotic microsurgery at leading institutions around the world,” said MMI CEO Mark Toland. “Now, our focus is translating that adoption into scale.”
BioStar Capital led the latest round, with participation from new investors S3 Ventures, Angelini Ventures, and an undisclosed strategic corporate investor.
Building Clinical Evidence and Expanding Capabilities
Beyond commercial expansion, MMI intends to channel the capital into additional clinical data generation and product development. Priority areas include energy instruments and enhanced digital surgery features. A key focus remains the REMIND clinical trial, which is examining the safety and feasibility of using Symani to restore drainage pathways in the deep cervical lymph nodes of patients with neurodegenerative disease. The underlying goal is to improve clearance of neurotoxins believed to play a role in Alzheimer’s progression.
The FDA authorized an expansion of the REMIND study this summer, increasing enrollment to 15 patients. Toland noted that research of this kind helps map the future of robotic microsurgery and highlighted the “remarkable” opportunities ahead.
With this new funding, MMI aims to convert early clinical adoption into broader commercial scale while continuing to explore new therapeutic frontiers for its technology.